The Netherlands
SkylineDx BV is a biotechnology and healthcare company founded in 2005, based in The Netherlands. The company's mission is to improve patients' quality of life by providing personalized insights at the genomic level of their disease through gene signature-based diagnostic testing.
The company's approach is centered around the principle of personalized or precision medicine, which aims to tailor treatment plans for each individual patient based on their unique genetic makeup. This approach is becoming increasingly important in the field of healthcare, as it allows for more effective treatment plans and ultimately better quality of life for patients.
SkylineDx BV has garnered interest from investors, with its most recent venture round investment occurring on 21 December 2021. The investment was led by Novalis LifeSciences and Van Herk Ventures, indicating the confidence these prominent investors have in the company's mission and potential impact on the healthcare industry.
With its innovative approach to gene signature-based diagnostic testing and the focus on personalized medicine, SkylineDx BV is well-positioned to contribute significantly to the advancement of patient care and disease treatment.
